The document discusses the progressive cognitive impairment, autonomy loss, and mobility issues in NPCD patients, highlighting thalamus abnormalities and the association of body-mass index with adverse events. It also notes the impact of Miglustat on UCHL1 levels in patients.
- Pages
- 16
- Published in
- United States of America
